Investigational Drug Details
| Drug ID: | D375 |
| Drug Name: | Cefazolin |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01327 |
| DrugBank Description: | A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. |
| PubChem ID: | 33255 |
| CasNo: | 25953-19-9 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O |
| Structure: |
|
| InChiKey: | MLYYVTUWGNIJIB-BXKDBHETSA-N |
| Molecular Weight: | 454.507 |
| DrugBank Targets: | Penicillin-binding protein 1A; Penicillin-binding protein 1B; Penicillin-binding protein 1C; Penicillin-binding protein 2; Peptidoglycan synthase FtsI; Serum paraoxonase/arylesterase 1; Interleukin-15; Interleukin-2 |
| DrugBank MoA: | In vitro tests demonstrate that the bactericidal action of cephalosporins results from inhibition of cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. |
| DrugBank Pharmacology: | Cefazolin (also known as cefazoline or cephazolin) is a semi-synthetic first generation cephalosporin for parenteral administration. Cefazolin has broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. |
| DrugBank Indication: | Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L3185 | NCT01497574 | PHASE1 | COMPLETED | NO | 2005-05 | 2017-01-30 | Details |
| L3639 | NCT01614769 | PHASE1 | COMPLETED | YES | 2012-07-18 | 2018-08-16 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|